Novo Nordisk Launches Subscription Program for Wegovy Obesity Drug

On March 31, 2026, Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug, aimed at providing cash-paying patients with lower and more predictable monthly prices. Eligible patients can select from three, six, or twelve-month plans for both the injectable and pill forms of Wegovy. The subscription model is designed to alleviate the financial burden associated with obesity treatment, with potential savings of up to $1,200 annually for the injection and $600 for the pill, compared to traditional monthly pricing.

QuartzCNBCForbesReutersBloomberg

Patients who opt for a 12-month subscription will pay $249 per month, which is significantly lower than the standard monthly price of $349 for the injection and $299 for the pill. The program is available through telehealth partners such as Ro, WeightWatchers, LifeMD, and will soon include Hims & Hers and Sesame. Notably, the subscription allows patients to maintain a flat monthly price even if they switch doses during the subscription period.

Quartz

The introduction of this subscription program comes amid increasing competition in the obesity drug market, particularly from Eli Lilly, which holds a significant market share with its GLP-1 drug, Zepbound. Analysts have noted that Novo Nordisk's previous delays in adopting direct-to-consumer strategies may have cost them market share. The subscription model is part of Novo's broader strategy to regain competitiveness by simplifying access and pricing for patients who pay out of pocket, as many insurance plans do not cover weight-loss medications.

Bloomberg

Staying on GLP-1 medications has been a persistent challenge, with studies indicating that approximately 65% of patients discontinue treatment within a year due to high costs, accessibility issues, and side effects. The subscription program aims to address these barriers by providing a more manageable payment structure, which could help improve patient adherence to treatment.

CNBC

Ed Cinca, Novo's senior vice president of marketing and patient solutions, emphasized that the subscription program is designed to "remove barriers" and provide a "simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment." He noted that the program is intended to help patients manage pricing uncertainty over time.

Quartz

Despite the potential benefits, some analysts express concern that Novo's aggressive pricing strategy may threaten profit margins in a competitive market. Eli Lilly has also indicated interest in developing a subscription model, which could further intensify competition.

Reuters

As the subscription program rolls out, Novo Nordisk plans to introduce a new high-dose Wegovy injection to the subscription offerings later this year. Additionally, Eli Lilly's oral obesity drug is under FDA review, with approval expected in the second quarter of 2026, which could further impact the competitive landscape.

Forbes

• “The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment,” — Ed Cinca, Senior Vice President of Marketing and Patient Solutions, Novo Nordisk.

Quartz

• “What we can do is take learnings from other industries that were able to reduce consumer friction,” — Dave Ricks, CEO of Eli Lilly.

Bloomberg